1990 - 2002年英格兰北部儿童和青年白血病及淋巴瘤的流行病学情况

Epidemiology of leukaemia and lymphoma in children and young adults from the north of England, 1990-2002.

作者信息

Feltbower Richard G, McNally Richard J Q, Kinsey Sally E, Lewis Ian J, Picton Susan V, Proctor Stephen J, Richards Michael, Shenton Geoff, Skinner Rod, Stark Daniel P, Vormoor Josef, Windebank Kevin P, McKinney Patricia A

机构信息

University of Leeds, Paediatric Epidemiology Group, Centre for Epidemiology and Biostatistics, Worsley Building, Clarendon Way, Leeds LS2 9JT, UK.

出版信息

Eur J Cancer. 2009 Feb;45(3):420-7. doi: 10.1016/j.ejca.2008.09.020. Epub 2008 Nov 12.

DOI:10.1016/j.ejca.2008.09.020

PMID:19004628

Abstract

AIM

We aimed to describe and contrast the epidemiology of haematological malignancies among 0-14 and 15-24-year-olds in northern England from 1990 to 2002 and compare clinical trial entry by age group.

PATIENTS AND METHODS

Incidence rates were examined by age, sex and period of diagnosis and differences were tested using Poisson regression. Differences and trends in survival were assessed using Cox regression.

RESULTS

1680 subjects were included comprising 948 leukaemias and 732 lymphomas. Incidence rates for acute lymphoblastic leukaemia were significantly higher for 0-14 compared to 15-24-year-olds, whilst Hodgkin lymphoma showed the reverse. No significant changes in incidence were observed. 60% of leukaemia patients aged 15-24 years entered trials compared to 92% of 0-14-year-olds. Survival rates were significantly lower and improved less markedly over time for 15-24 compared to 0-14-year-olds, particularly for leukaemia.

CONCLUSIONS

Trial accrual rates need to be improved amongst 15-24-year-olds and a more structured follow-up approach adopted for this unique population.

摘要

目的

我们旨在描述和对比1990年至2002年英格兰北部0至14岁和15至24岁人群血液系统恶性肿瘤的流行病学情况，并比较不同年龄组进入临床试验的情况。

患者与方法

按年龄、性别和诊断时期检查发病率，并使用泊松回归检验差异。使用Cox回归评估生存差异和趋势。

结果

纳入1680名受试者，其中包括948例白血病和732例淋巴瘤。0至14岁儿童急性淋巴细胞白血病的发病率显著高于15至24岁人群，而霍奇金淋巴瘤则相反。未观察到发病率有显著变化。15至24岁白血病患者中有60%进入试验，而0至14岁患者中这一比例为92%。与0至14岁人群相比，15至24岁人群的生存率显著较低，且随时间改善的幅度较小，尤其是白血病患者。